Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78


Targeted identification of infection-related HLA class I-presented epitopes by stable isotope tagging of epitopes (SITE).

Meiring HD, Soethout EC, de Jong AP, van Els CA.

Curr Protoc Immunol. 2007 May;Chapter 16:Unit 16.3. doi: 10.1002/0471142735.im1603s77.


Stable isotope tagging of epitopes: a highly selective strategy for the identification of major histocompatibility complex class I-associated peptides induced upon viral infection.

Meiring HD, Soethout EC, Poelen MC, Mooibroek D, Hoogerbrugge R, Timmermans H, Boog CJ, Heck AJ, de Jong AP, van Els CA.

Mol Cell Proteomics. 2006 May;5(5):902-13. Epub 2006 Jan 23.


Long-term immunity against actual poxviral HLA ligands as identified by differential stable isotope labeling.

Meyer VS, Kastenmuller W, Gasteiger G, Franz-Wachtel M, Lamkemeyer T, Rammensee HG, Stevanovic S, Sigurdardottir D, Drexler I.

J Immunol. 2008 Nov 1;181(9):6371-83.


Mass tag-assisted identification of naturally processed HLA class II-presented meningococcal peptides recognized by CD4+ T lymphocytes.

Meiring HD, Kuipers B, van Gaans-van den Brink JA, Poelen MC, Timmermans H, Baart G, Brugghe H, van Schie J, Boog CJ, de Jong AP, van Els CA.

J Immunol. 2005 May 1;174(9):5636-43.


A single naturally processed measles virus peptide fully dominates the HLA-A*0201-associated peptide display and is mutated at its anchor position in persistent viral strains.

van Els CA, Herberts CA, van der Heeft E, Poelen MC, van Gaans-van den Brink JA, van der Kooi A, Hoogerhout P, Jan ten Hove G, Meiring HD, de Jong AP.

Eur J Immunol. 2000 Apr;30(4):1172-81.


Rapid and sensitive identification of major histocompatibility complex class I-associated tumor peptides by Nano-LC MALDI MS/MS.

Hofmann S, Glückmann M, Kausche S, Schmidt A, Corvey C, Lichtenfels R, Huber C, Albrecht C, Karas M, Herr W.

Mol Cell Proteomics. 2005 Dec;4(12):1888-97. Epub 2005 Aug 19.


Discovery of naturally processed and HLA-presented class I peptides from vaccinia virus infection using mass spectrometry for vaccine development.

Johnson KL, Ovsyannikova IG, Mason CJ, Bergen HR 3rd, Poland GA.

Vaccine. 2009 Dec 10;28(1):38-47. doi: 10.1016/j.vaccine.2009.09.126. Epub 2009 Oct 12.


Mass spectrometry of human leukocyte antigen class I peptidomes reveals strong effects of protein abundance and turnover on antigen presentation.

Bassani-Sternberg M, Pletscher-Frankild S, Jensen LJ, Mann M.

Mol Cell Proteomics. 2015 Mar;14(3):658-73. doi: 10.1074/mcp.M114.042812. Epub 2015 Jan 9.


The viral transcription group determines the HLA class I cellular immune response against human respiratory syncytial virus.

Johnstone C, Lorente E, Barriga A, Barnea E, Infantes S, Lemonnier FA, David CS, Admon A, López D.

Mol Cell Proteomics. 2015 Apr;14(4):893-904. doi: 10.1074/mcp.M114.045401. Epub 2015 Jan 29.


Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine.

Tsang KY, Zaremba S, Nieroda CA, Zhu MZ, Hamilton JM, Schlom J.

J Natl Cancer Inst. 1995 Jul 5;87(13):982-90.


HIV-1-specific cytotoxic T lymphocyte (CTL) responses against immunodominant optimal epitopes slow the progression of AIDS in China.

Zhai S, Zhuang Y, Song Y, Li S, Huang D, Kang W, Li X, Liao Q, Liu Y, Zhao Z, Lu Y, Sun Y.

Curr HIV Res. 2008 Jun;6(4):335-50.


A microcapillary column switching HPLC-electrospray ionization MS system for the direct identification of peptides presented by major histocompatibility complex class I molecules.

van der Heeft E, ten Hove GJ, Herberts CA, Meiring HD, van Els CA, de Jong AP.

Anal Chem. 1998 Sep 15;70(18):3742-51.


Correlations between Terasaki's HLA class I epitopes and HLAMatchmaker-defined eplets on HLA-A, -B and -C antigens.

Duquesnoy RJ, Marrari M.

Tissue Antigens. 2009 Aug;74(2):117-33. doi: 10.1111/j.1399-0039.2009.01271.x. Epub 2009 Jun 2.


Immunodominance among EBV-derived epitopes restricted by HLA-B27 does not correlate with epitope abundance in EBV-transformed B-lymphoblastoid cell lines.

Crotzer VL, Christian RE, Brooks JM, Shabanowitz J, Settlage RE, Marto JA, White FM, Rickinson AB, Hunt DF, Engelhard VH.

J Immunol. 2000 Jun 15;164(12):6120-9.


Immunodominance across HLA polymorphism: implications for cancer immunotherapy.

Kim CJ, Parkinson DR, Marincola F.

J Immunother. 1998 Jan;21(1):1-16. Review.


Supplemental Content

Support Center